Literature DB >> 35024939

Case series of congenital pseudarthrosis of the tibia unfulfilling neurofibromatosis type 1 diagnosis: 21% with somatic NF1 haploinsufficiency in the periosteum.

Yu Zheng1,2,3, Guanghui Zhu2, Yaoxi Liu2, Weihua Zhao2, Yongjia Yang2, Zhenqing Luo2, Yuyan Fu2, Haibo Mei4, Zhengmao Hu5,6.   

Abstract

Up to 84% of patients with congenital pseudarthrosis of the tibia (CPT) present with neurofibromatosis type 1 (NF1) (NF1-CPT). However, the etiology of CPT not fulfilling the NIH diagnostic criteria for NF1 (non-NF1-CPT) is not well understood. Here, we collected the periosteum tissue from the pseudarthrosis (PA) site of 43 non-NF1-CPT patients and six patients with NF1-CPT, together with the blood or oral specimen of trios (probands and unaffected parents). Whole-exome plus copy number variation sequencing, multiplex ligation-dependent probe amplification (MLPA), ultra-high amplicon sequencing, and Sanger sequencing were employed to identify pathogenic variants. The result showed that nine tissues of 43 non-NF1-CPT patients (21%) had somatic mono-allelic NF1 inactivation, and five of six NF1-CPT patients (83.3%) had bi-allelic NF1 inactivation in tissues. However, previous literature involving genetic testing did not reveal somatic mosaicism in non-NF1-CPT patients so far. In NF1-CPT patients, when the results from earlier reports and the present study were combined, 66.7% of them showed somatic NF1 inactivation in PA tissues other than germline inactivation. Furthermore, no diagnostic variants from other known genes (GNAS, AKT1, PDGFRB, and NOTCH3) related to skeletal dysplasia were identified in the nine NF1 positive non-NF1-CPT patients and six NF1-CPT patients. In conclusion, we detected evident somatic mono-allelic NF1 inactivation in the non-NF1-CPT. Thus, for pediatric patients without NF1 diagnosis, somatic mutations in NF1 are important.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Mesh:

Year:  2022        PMID: 35024939     DOI: 10.1007/s00439-021-02429-2

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   5.881


  65 in total

Review 1.  NF1 tumor suppressor gene function: narrowing the GAP.

Authors:  K Cichowski; T Jacks
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.

Authors:  T N Basu; D H Gutmann; J A Fletcher; T W Glover; F S Collins; J Downward
Journal:  Nature       Date:  1992-04-23       Impact factor: 49.962

3.  Neurofibromatosis type 1-related pseudarthrosis: Beyond the pseudarthrosis site.

Authors:  Carlijn Brekelmans; Silke Hollants; Caroline De Groote; Natalie Sohier; Marina Maréchal; Liesbet Geris; Frank P Luyten; Lieve Ginckels; Raf Sciot; Thomy de Ravel; Luc De Smet; Johan Lammens; Eric Legius; Hilde Brems
Journal:  Hum Mutat       Date:  2019-06-18       Impact factor: 4.878

4.  Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.

Authors:  D G Evans; E Howard; C Giblin; T Clancy; H Spencer; S M Huson; F Lalloo
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

5.  A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity.

Authors:  L B Andersen; R Ballester; D A Marchuk; E Chang; D H Gutmann; A M Saulino; J Camonis; M Wigler; F S Collins
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

6.  Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Authors:  G Bollag; D W Clapp; S Shih; F Adler; Y Y Zhang; P Thompson; B J Lange; M H Freedman; F McCormick; T Jacks; K Shannon
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

7.  Congenital pseudarthrosis of the tibia: the outcome of a pathology-oriented classification system and treatment protocol.

Authors:  Mahmoud Abdel-Monem El-Rosasy
Journal:  J Pediatr Orthop B       Date:  2020-07       Impact factor: 1.041

8.  A framework for variation discovery and genotyping using next-generation DNA sequencing data.

Authors:  Mark A DePristo; Eric Banks; Ryan Poplin; Kiran V Garimella; Jared R Maguire; Christopher Hartl; Anthony A Philippakis; Guillermo del Angel; Manuel A Rivas; Matt Hanna; Aaron McKenna; Tim J Fennell; Andrew M Kernytsky; Andrey Y Sivachenko; Kristian Cibulskis; Stacey B Gabriel; David Altshuler; Mark J Daly
Journal:  Nat Genet       Date:  2011-04-10       Impact factor: 38.330

9.  SAMBLASTER: fast duplicate marking and structural variant read extraction.

Authors:  Gregory G Faust; Ira M Hall
Journal:  Bioinformatics       Date:  2014-05-07       Impact factor: 6.937

10.  Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only.

Authors:  D G Evans; N Bowers; E Burkitt-Wright; E Miles; S Garg; V Scott-Kitching; M Penman-Splitt; A Dobbie; E Howard; J Ealing; G Vassalo; A J Wallace; W Newman; S M Huson
Journal:  EBioMedicine       Date:  2016-04-13       Impact factor: 8.143

View more
  1 in total

1.  Clinical characteristics and in silico analysis of congenital pseudarthrosis of the tibia combined with neurofibromatosis type 1 caused by a novel NF1 mutation.

Authors:  Jingfang Xu; Ying Zhang; Kun Zhu; Jiabin Li; Yuelin Guan; Xinyu He; Xuejing Jin; Guannan Bai; Lidan Hu
Journal:  Front Genet       Date:  2022-09-28       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.